Aurinia Pharmaceuticals Inc

NASDAQ:AUPH   9:48:56 AM EDT
19.10
+4.24 (+28.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.42B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.04 Million
Adjusted EPS-$0.30
See more estimates
10-Day MA$15.17
50-Day MA$14.15
200-Day MA$14.97
See more pivots

Aurinia Pharmaceuticals Inc. Stock, NASDAQ:AUPH

#1203-4464 MARKHAM STREET, VICTORIA BC, CANADA V8Z 7X8
Canada
Phone: 250-708-4272
Number of Employees: 15

Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.